RBM46

Across TCGA pan-cancer cohorts, RBM46 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBM46 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher RBM46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RBM46 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRC, LGG, and PRAD are the cancer types where RBM46 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.123	0.805	<.001	42	view →
LGG	DFS	Median	All	0.167	0.739	<.001	15	view →
PRAD	DFS	Median	All	0.086	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.944	0.661	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBM46–KIRC (OS)

Open the KIRC breakdown →